La Jolla Pharma Gets FDA Approval for Blood Pressure Drug

 

Last week, La Jolla Pharmaceutical Company ( LJPC) received FDA approval for their low blood pressure injectible Giapreza

The intravenous injectible is used to raise blood pressure in adults with certain symptoms like sepsis, shock, and hypertension, but can also cause dangerous blood clots. The agency warns that use of this drug should be in conjunction with prophylactic treatments. 

In a 321 patient clinical trial Giapreza raised blood pressure against placebo tests, and received a 'Priority Review' from the FDA, which expedites application actions to within 6 months. You can read the full press release here.

 

ABOUT US

© New Kapitall Holdings LLC. All rights reserved. Kapitall Wire is a division of New Kapitall Holdings LLC. Kapitall Generation, LLC is a wholly owned subsidiary of New Kapitall Holdings LLC. Kapitall Wire, which is not a broker/dealer, offers free cutting edge content and commentary and is produced for informational purposes only and should not be construed as research. Kapitall Wire is a product offered by New Kapitall Holdings, however, KapGen compliance personnel will oversee all Kapitall Wire material prior to release.

 

More from Stocks

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Video: Here's How Goldman Sachs May Change Under David Solomon

Video: Here's How Goldman Sachs May Change Under David Solomon

J&J Vows to Fight Verdict Linking Baby Powder to Ovarian Cancer

J&J Vows to Fight Verdict Linking Baby Powder to Ovarian Cancer

3 Reasons Why Netflix Bulls Are Getting Their Face Ripped Off After Earnings

3 Reasons Why Netflix Bulls Are Getting Their Face Ripped Off After Earnings

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony